
ããªãããã·ã¢ãšãŠã¯ã©ã€ãã«æ°ãåãããŠããéã«ãè±åœæ¿åºã¯äžç𮿷·åã¯ã¯ãã³æ¥çš®è ãåŸå€©æ§å ç«äžå šçå矀ãçºçããŠããããã ãšæããã«ããã
å èšäºã¯ãã¡ã/Original article here
åŸå€©æ§å ç«äžå šçå矀ïŒAIDSïŒã¯ãHIVãŠã€ã«ã¹ã ããåå ã§ãããšããã®ã¯ãããã誀解ã§ããããã¯åã«çå®ã§ã¯ãããŸããã
ãšã€ãºã«ã¯ããŸããŸãªåå ããããŸãããæ®å¿µãªãããè±åœæ¿åºã®å ¬åŒããŒã¿ã«ãããšãè±åœã®äžç𮿷·åã¯ã¯ãã³æ¥çš®è ã2022幎åãããçºçããŠãããšã®ããšãªã®ã§ãã³ãã19泚å°ãåå ã®ãªã¹ãã«å ããªããã°ãªããªãããã§ãã

åŸå€©æ§ïŒãŸãã¯äºæ¬¡æ§ïŒå
ç«äžå
šçã¯ãæäººã®ææçã®äž»ãªåå ã®äžã€ã§ãããããã®å
ç«äžå
šçã¯ãå
ç«ç³»ã®äžéšãŸãã¯å
šäœã«åœ±é¿ãäžããäœãããã€ãã®ç
æ°ãææçã®ã¿ãŒã²ããã«ããããããŸãã(åºå
ž)
å
ç«äžå
šé害ãå
ç«ç³»ã«åœ±é¿ãäžãããšãããªãã®äœã¯ãã¯ã现èãç
æ°ãšæŠãããšãã§ããªããªããŸãã(åºå
ž)
ç°å¢äžã®ããã€ãã®èŠå ã¯ãäºæ¬¡çãªå
ç«äžå
šé害ãåŒãèµ·ããå¯èœæ§ããããŸãã(åºå
ž)
äžè¬çãªãã®ãããã€ã玹ä»ããŸãã
æŸå°ç·çæ³ãååŠçæ³ã«ããã奜äžçæžå°çãšããŠç¥ãããäºæ¬¡çãªå ç«äžå šé害ãåŒãèµ·ããå¯èœæ§ãããã
ããå ç«äžå šãŠã€ã«ã¹ïŒHIVïŒã«ããææçã¯ãåŸå€©æ§å ç«äžå šçå矀ïŒAIDSïŒãåŒãèµ·ããå¯èœæ§ããããŸãã
çœè¡ç ã¯ã骚é«ã®çްèããå§ãŸãçã§ãäºæ¬¡æ§å ç«äžå šã®äžçš®ã§ããäœã¬ã³ãã°ãããªã³è¡çãåŒãèµ·ããå¯èœæ§ããããŸãã
æ é€å€±èª¿ïŒäœéçºåœã®äººå£ã®50ïŒ ã眹æ£ããåŒåžåšææçãäžç¢ã«çœ¹æ£ããããã
ããããããŸãäžè¬çã§ãªãåå ãšããŠã¯ããè¬ãããè¬å€ãããããŸãã(åºå ž)
ã€ãŸããè¬ãè¬å€ãåŸå€©æ§å ç«äžå šçå矀ãåŒãèµ·ããå¯èœæ§ã¯ååã«ãããè±åœå¥åº·å®å šå±ãçºè¡šããããŒã¿ã§ã¯ãCovid-19泚å°ããã®ãªã¹ãã«å ããããã¹ãã ãšåŒ·ã瀺åãããŠããã®ã§ãã
以äžã®ã°ã©ãã¯ã2022幎1æ3æ¥ãã3æ27æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19ã®ç·æ£è æ°ãã幎霢局ãšé±ã§åºåã£ãŠç€ºãããã®ã§ãããããŒã¿ã¯ã第5é±ãïŒ43ããŒãžïŒã第9é±ïŒ41ããŒãžïŒã第13é±ïŒ41ããŒãžïŒUKHSA Covid-19 Vaccine Surveillance report -ããæœåºãããã®ã§ããã

次ã®ã°ã©ãã¯ãäžã®ã°ã©ãã®æ°å€ãããšã«ãã€ã³ã°ã©ã³ãã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®Covid-19æ£è ã®å²åã瀺ãããã®ã§ããŒã

ãã®ããã«ãå°ãªããšã幎æã以éã3皮混åã¯ã¯ãã³ãæ¥çš®ããŠãããã¹ãŠã®å¹Žéœ¢å±€ã§ãæ£è æ°ãæãå€ããªã£ãŠããããšãããããããã ãããšæããŸããå€ãã®äººãã¯ã¯ãã³ãæ¥çš®ããŠããã®ã ãããããã¯äœã®æå³ããªããšãæãã§ãããã
ãŸãããã®ããŒã¿ã ãã§ããå°ãªããšãã³ããã19ã®æ³šå°ãæããã«ææãé²ãã§ããªãããšãããããããããUKHSAã¯ãäœããæ·±å»ã«ééã£ãŠããããšã瀺ããããªãæ°åãæäŸããŠãããŠããããã®æ°åãšã¯ãã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®ã³ããã-19çäŸçã§ããã
次ã®å³ã¯ã2022幎1æ3æ¥ãã3æ27æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ãããã¯ã¯ãã³æ¥çš®ç¶æ³å¥ã®10äžäººåœããã®Covid-19æ£è çãã幎霢局ãšé±ã§åããŠç€ºãããã®ã§ãããããŒã¿ã¯ã第5é±ïŒ47ããŒãžïŒã第9é±ïŒ45ããŒãžïŒã第13é±ïŒ45ããŒãžïŒã®UKHSA Covid-19ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹ã¬ããŒãããæç²ãããã®ã§ããã

ãã®æ°åã«ãããšããã¹ãŠã®å¹Žéœ¢å±€ã§3皮混åã¯ã¯ãã³æ¥çš®è ã®ææçãæãé«ããªã£ãŠããããããããã®å·®ã¯ã»ãã®å°ãã§ã¯ãªãã100äžãã€ã«ãããããããŠãã¯ã¯ãã³æªæ¥çš®è ãš3皮混åã¯ã¯ãã³æ¥çš®è ã®éã®å·®ã¯ãæããšã«æªåããŠããã
ãããã£ãŠããããã®æ°åã¯ãå°ãªããšãã³ããã19ã®æ³šå°ãåãã人ããã¯ã¯ãã³æªæ¥çš®ã®äººãããã³ããã19ã«ææããå¯èœæ§ãé«ãããšã瀺åããŠãããããã«ã¯èª¬æãå¿ èŠã§ãããåŸå€©æ§å ç«äžå šçå矀ã¯ããã®è¯ã説æã®äžã€ã§ããã
ãªããªãããã®èšäºã®åé ã§æããã«ããããã«-ã
å ç«äžå šçã¯ãå ç«ç³»ã®äžéšãŸãã¯å šäœã«åœ±é¿ãäžããäœãããã€ãã®ç æ°ãææçã®æšçã«ããããããŸãã(åºå ž)
å ç«äžå šé害ãå ç«ç³»ã«åœ±é¿ãäžãããšãããªãã®äœã¯ãã¯ã现èãç æ°ãšæŠãããšãã§ããªããªããŸãã(åºå ž)
ããããäžèšã®çäŸæ°ã°ã©ãã§ã¯ãããã«ãããããã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æèšç®åŒã®ãããã§ããã®æ°åã䜿ã£ãŠã3åæ¥çš®è ã®å®éã®Covid-19ã¯ã¯ãã³å¹æãèšç®ãããã®æžå°ã®æ·±å»ããå¯èŠåããããšãã§ããã®ã ã
ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³å¹æã®èšç®åŒã¯ä»¥äžã®éãã§ãã
æªæ¥çš®äŸç-æ¥çš®äŸçïŒæªæ¥çš®äŸçÃ100ïŒã¯ã¯ãã³å¹æç
2022幎1æ3æ¥ãã3æ27æ¥ãŸã§ã®ã€ã³ã°ã©ã³ãã«ããã3åæ¥çš®è ã®å¹Žéœ¢å±€å¥ãé±å¥ã®Covid-19ã¯ã¯ãã³å¹æã®å®æž¬å€ããäžèšã°ã©ãã®çäŸçã«åºã¥ã瀺ãããã®ããã¡ãã§ãã

ããã§ã¯ããã¡ã€ã¶ãŒç€Ÿã䞻匵ããæå¹ç95ïŒ ã«ã¯å°åºåã°ãªãã®ã§ã¯ãªãã ãããïŒã¯ã¯ãã³å¹æã¯ã第5é±ã®ãã€ãã¹114.8%ããã第13é±ã«ã¯60-69æ³ã®éã§ãã€ãã¹391.43%ãŸã§äœäžããŠããã
æ¬¡ã®æãç·ã°ã©ãã¯ãå幎霢局ã§ã®ãã®æžå°ãããæç¢ºã«ç€ºããŠããã

æãæ°ã«ãªãã®ã¯ã60-69 æ³ãš 70-79 æ³ã§ã第9é±ãšç¬¬13é±ã®éã«åŽã£ã·ã¡ã«ãªã£ãŠããããã«èŠããããããããããšã«ã18-29 æ³ã®èœã¡èŸŒã¿ã¯ã第9é±ãã第13é±ã«ãããŠéåããŠããããã ããããã§ã第5é±ã®ãã€ãã¹29.8ïŒ ãããã€ãã¹231.22ïŒ ã«ãšã©ãŸã£ãŠããã
ãã®æ°åã¯ã60-69æ³ãã¯ã¯ãã³æªæ¥çš®ã®60-69æ³ãã5åè¿ãCovid-19ã«ææããããããšã瀺ããŠããã40-59æ³ãš70-79æ³ãã¯ã¯ãã³æªæ¥çš®ã®å幎代ãã4å以äžCovid-19ã«ææããå¯èœæ§ãããããšã瀺ããŠããŸãã
UKHSAã¯ãã¯ã¯ãã³ã®å¹æã¯æéã®çµéãšãšãã«å€§å¹ ã«è¡°ããã®ã§ãããŒã¹ã¿ãŒæäžãåããããšãéèŠã ãšäž»åŒµããŠããŸããããããããã¯åã§ãããã¯ã¯ãã³ã®å¹æã¯è¡°ããŸãããå ç«ç³»ã®æ§èœãäœäžããã®ã§ãã
ã¯ã¯ãã³ã®æå¹æ§ã¯ã¯ã¯ãã³ãè©äŸ¡ãããã®ã§ã¯ãªããã¯ã¯ãã³æ¥çš®ãåãã人ã®å ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ããã¯ã¯ãã³æªæ¥çš®ã®äººã®å ç«ã·ã¹ãã ã®ããã©ãŒãã³ã¹ãšæ¯èŒãããã®ãªã®ã§ãã
ã¯ã¯ãã³å¹æã-50ïŒ ãšããããšã¯ãã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ãã¯ã¯ãã³æªæ¥çš®è ã®èªç¶å ç«ç³»ãããæªãå²åã§æ©èœããŠããããšãæå³ããŸããããã¯ãCovid-19ã¯ã¯ãã³ãå ç«ç³»ã«ãã¡ãŒãžãäžããããšãæå³ãããŸãã«ãã®æ°åã瀺ããŠããéããªã®ã§ãã
UKHSAããæäŸãããçäŸæ°ã䜿ã£ãŠãå ç«ã·ã¹ãã ã®æ§èœãèšç®ããããšãã§ããŸããå¿ èŠãªããšã¯ãã¯ã¯ãã³å¹æã®èšç®åŒãå°ãå€ããŠãå ç«ç³»ã®ããã©ãŒãã³ã¹ãè² ã«ãªãããã«ããåãèšç®åŒã§å ç«ç³»ã®ããã©ãŒãã³ã¹ãæ£ã«ãªãããã«ããããšã§ãã
ããžãã£ããªå
ç«ç³»ããã©ãŒãã³ã¹ïŒæªæ¥çš®çäŸç-ã¯ã¯ãã³æ¥çš®çäŸçïŒæªæ¥çš®çäŸçÃ100
è² ã®å
ç«ç³»ããã©ãŒãã³ã¹ïŒæªæ¥çš®çäŸæ°-ã¯ã¯ãã³æ¥çš®çäŸæ°ïŒã¯ã¯ãã³æ¥çš®çäŸæ°Ã100
次ã®å³ã¯ãäžèšã®çäŸçã«åºã¥ããã€ã³ã°ã©ã³ãã®3皮混åã¯ã¯ãã³æ¥çš®è ã®å ç«ç³»ããã©ãŒãã³ã¹ã幎霢局å¥ã«1é±éåœããã§ã¯ã¯ãã³æªæ¥çš®è ã®èªç¶å ç«ç³»ãšæ¯èŒãããã®ã§ããã

æãå ç«åãäœãã®ã¯60ïœ69æ³ã®ãã€ãã¹80ïŒ ã ãã30ïœ59æ³ã®ããªãã«ã¯ã¯ãã³æ¥çš®è å šå¡ãããã€ãã¹75ïŒ ïœãã€ãã¹76ïŒ ãšã倧ããåŒãé¢ãããŠããªãã
18ïœ29æ³ã§ããã€ãã¹70ïŒ ã§ã51é±ç®ãã2é±ç®ã«ãããŠ+11.35ïŒ ã ã£ãå ç«åãããã®é åã«å ¥ã£ãŠãããæãæ©ãå ç«åãäœäžããŠããããšã«ãªãã
æ¬¡ã®æãç·ã°ã©ãã¯ãå幎霢局ã«ãããå ç«ç³»ã®ããã©ãŒãã³ã¹ã®äœäžãããæç¢ºã«ç€ºããŠããŸãã

60æ³ä»¥äžã§3åã®ãžã£ããåãã人ã¯ã2022幎ã«å ¥ã£ãŠããå ç«ã·ã¹ãã ã®æ§èœã極ããŠæ¥éã«äœäžããŠããããšãæããã«ãªã£ãã®ã§ãäžèšã®æ°åã«åºã¥ããŠéåžžã«å¿é ããå¿ èŠããããŸãã
ãããã60æ³æªæºã®äººã¯å¿é ããªããŠãããšããããã§ã¯ãªãããã§ã«å¹³åã§70ïœ76ïŒ äœäžããå ç«ã·ã¹ãã ã«æ©ãŸãããŠãã人ã°ããã§ãã
ããããè±åœå¥åº·å®å šå±ã¯éœåãã第13é±ã®å ±åæžãçºè¡šããåŸãæ°å€ã®å ¬è¡šãäžæ¢ããããšã«ããã®ã§ãä»åŸã®æžå°ãå ¬åŒã«ç¢ºèªããããšã¯ã§ããªããåŸã£ãŠããã®å ç«ã·ã¹ãã ã®æ§èœäœäžã®çµæãå®ãçµãã ãšãããã§ã«æäžæ¯ã®NHSãã©ã®ããã«å¯ŸåŠããããèŠå®ããããªãã ããã
åºå žã»åèæç®
COVID-19ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã2022幎2æ3æ¥ïŒç¬¬5é±ïŒ
COVID-19ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã2022幎3æ3æ¥ïŒ9é±ç®ïŒ
COVID-19ã¯ã¯ãã³ãµãŒãã€ã©ã³ã¹å ±åæžã2022幎3æ31æ¥ïŒç¬¬13é±ïŒ